A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

Clinical trial NCT04996797 · COMPLETED

Trial details

NCT number: NCT04996797
Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Ulcerative Colitis

Start date: 2021-07-14
Primary completion: 2023-06-06
Enrollment: 178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.